Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Cheek Swab Test Could Identify Biomarkers for Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 14 Dec 2021

Cells from a cheek swab revealed biomarkers for rheumatoid arthritis that could lead to a way to diagnose and begin treatment before the disease develops, according to a new study. More...

In the study, researchers from Washington State University (Pullman, WA, USA) and Arthritis Northwest (Spokane, WA, USA) identified a set of epimutations in cells from women who had rheumatoid arthritis that were distinct from those without the joint-damaging autoimmune disease. Epimutations are molecular factors and processes around DNA that regulate genome activity, independent of DNA sequence. The discovery could advance treatment for rheumatoid arthritis. While current drug treatments have limited efficacy in many patients who have already developed the disease, some studies have shown that treatments begun in early stages of the disease can cause remission of symptoms. Having biomarkers could allow treatment to begin even earlier before the first signs of it start.

For the study, researchers collected buccal, or cheek, cells using a swab from two cohorts of women: a group of 26 Caucasian women and a group of 23 African-American women. In each group, about half of the women had rheumatoid arthritis with the other half serving as a control. Even though they are taken from the cheek, buccal cells allowed the researchers to conduct an epigenome-wide analysis. Translating literally as “above” the genome, an epigenome consists of chemical factors that can modify the genome and change its behavior. While not part of DNA itself, epimutations can still be passed down to subsequent generations.

In this study, the researchers found epimutations in areas called DNA methylation regions, among the women in both groups who had rheumatoid arthritis. The study was designed to see if there were differences between racial groups since African Americans have shown some signs of increased prevalence of rheumatoid arthritis. However, while some differences were noted, the researchers found a large overlap in epimutations among women with rheumatoid arthritis of both races, meaning the identified biomarkers hold a strong signal for the disease.

The findings add evidence that the disease is likely systemic, meaning it was found not just in immune system cells involved in rheumatoid arthritis development but in many different cells throughout the body. The research team also tested an immune-related monocyte cell type in blood samples from a portion of the women, but the buccal cells showed the epimutations as well, indicating that a relatively non-invasive diagnostic cheek swab test could be developed to screen for the disease.

“If we can identify these patients 10 years earlier before the disease develops, it opens up a whole arena of preventative medicine that we did not have access to before,” said Michael Skinner, a professor in WSU’s School of Biological Sciences.

Related Links:
Washington State University 
Arthritis Northwest 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.